BR112014018106A2 - composto, uso de um composto, e, método para tratar uma doença fibrótica - Google Patents

composto, uso de um composto, e, método para tratar uma doença fibrótica

Info

Publication number
BR112014018106A2
BR112014018106A2 BR112014018106A BR112014018106A BR112014018106A2 BR 112014018106 A2 BR112014018106 A2 BR 112014018106A2 BR 112014018106 A BR112014018106 A BR 112014018106A BR 112014018106 A BR112014018106 A BR 112014018106A BR 112014018106 A2 BR112014018106 A2 BR 112014018106A2
Authority
BR
Brazil
Prior art keywords
compound
fibrotic disease
treating fibrotic
treating
fibrotic
Prior art date
Application number
BR112014018106A
Other languages
English (en)
Inventor
John Thompson Vallance Patrick
Teresa Lukey Pauline
Francis Wooster Richard
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112014018106A2 publication Critical patent/BR112014018106A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1 / 1 resumo “composto, uso de um composto, e, mã‰todo para tratar uma doenã‡a fibrã“ticaâ€� a presente invenã§ã£o refere-se a compostos ou sais farmaceuticamente aceitã¡veis dos mesmos para uso no tratamento de doenã§as fibrã³ticas, tais como fibrose pulmonar idiopã¡tica (ipf).
BR112014018106A 2012-02-06 2013-02-04 composto, uso de um composto, e, método para tratar uma doença fibrótica BR112014018106A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595293P 2012-02-06 2012-02-06
US201261702854P 2012-09-19 2012-09-19
PCT/EP2013/052112 WO2013117503A2 (en) 2012-02-06 2013-02-04 Novel use

Publications (1)

Publication Number Publication Date
BR112014018106A2 true BR112014018106A2 (pt) 2017-06-27

Family

ID=47633093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018106A BR112014018106A2 (pt) 2012-02-06 2013-02-04 composto, uso de um composto, e, método para tratar uma doença fibrótica

Country Status (10)

Country Link
US (2) US20150051215A1 (pt)
EP (1) EP2812002A2 (pt)
JP (1) JP2015509483A (pt)
KR (1) KR20140127307A (pt)
CN (1) CN104093408A (pt)
AU (1) AU2013218148A1 (pt)
BR (1) BR112014018106A2 (pt)
CA (1) CA2861521A1 (pt)
RU (1) RU2014128387A (pt)
WO (1) WO2013117503A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
AU2016301113B2 (en) * 2015-07-30 2019-10-03 Monash University Fibrotic treatment
JP6419097B2 (ja) * 2016-01-14 2018-11-07 学校法人東京農業大学 ヤマノイモ属植物からのディオスコリンの製造方法
WO2018177301A1 (zh) 2017-04-01 2018-10-04 郑州大学 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa

Also Published As

Publication number Publication date
CA2861521A1 (en) 2013-08-15
RU2014128387A (ru) 2016-03-27
US20160067247A1 (en) 2016-03-10
WO2013117503A3 (en) 2013-10-03
CN104093408A (zh) 2014-10-08
AU2013218148A1 (en) 2014-07-24
WO2013117503A2 (en) 2013-08-15
KR20140127307A (ko) 2014-11-03
US20150051215A1 (en) 2015-02-19
JP2015509483A (ja) 2015-03-30
EP2812002A2 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
CY1119170T1 (el) Ενωση γουανιδινης
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UY34474A (es) Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C.
BR112015008987A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
BR112012033117A2 (pt) pirazolo[1,5-a]pirimidinas como agentes antivirais
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
IN2014DN09434A (pt)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201300869A1 (ru) Морфинановые соединения
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201892726A1 (ru) Дейтерированный палбоциклиб
BR112014018106A2 (pt) composto, uso de um composto, e, método para tratar uma doença fibrótica

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.